Who can use XALKORI(Crizotinib)?

XALKORI is indicated for the treatment of ALK or ROS1-positive metastatic NSCLC, ALK-positive systemic ALCL, and ALK-positive IMT.

Approved Uses of XALKORI

XALKORI is used in adult patients with metastatic NSCLC whose tumors are ALK or ROS1-positive, as confirmed by an FDA-approved test. It is also approved for pediatric patients and young adults with relapsed or refractory ALK-positive ALCL, and for both adult and pediatric patients with unresectable, recurrent, or refractory ALK-positive IMT. The safety and efficacy in older adults with ALCL have not been established.